Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in the Journal of Nuclear Medicine

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable to other agents as well. A study published in the July 2009 issue of The Journal of Nuclear Medicine confirms that In-Line labeling can dramatically reduce the complexity and cost of producing radiolabeled cancer drugs(1). In-Line labeling is already being used for the production of Peregrine's radiolabeled antibody Cotara(R), currently...

Want to see the full article?

• Purchase this article for only $3.00